- Home
- NDLS vs CVKD Comparison
NDLS vs CVKD Comparison
Compare NDLS & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- CVKD
- Stock Information
- Founded
- NDLS 1995
- CVKD 2022
- Country
- NDLS United States
- CVKD United States
- Employees
- NDLS N/A
- CVKD N/A
- Industry
- NDLS Restaurants
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- NDLS Consumer Discretionary
- CVKD Health Care
- Exchange
- NDLS Nasdaq
- CVKD Nasdaq
- Market Cap
- NDLS 32.9M
- CVKD 29.5M
- IPO Year
- NDLS 2013
- CVKD 2023
- Fundamental
- Price
- NDLS $0.80
- CVKD $12.68
- Analyst Decision
- NDLS Strong Buy
- CVKD Strong Buy
- Analyst Count
- NDLS 2
- CVKD 1
- Target Price
- NDLS $3.00
- CVKD $32.00
- AVG Volume (30 Days)
- NDLS 212.2K
- CVKD 33.5K
- Earning Date
- NDLS 08-06-2025
- CVKD 08-06-2025
- Dividend Yield
- NDLS N/A
- CVKD N/A
- EPS Growth
- NDLS N/A
- CVKD N/A
- EPS
- NDLS N/A
- CVKD N/A
- Revenue
- NDLS $495,670,000.00
- CVKD N/A
- Revenue This Year
- NDLS $5.37
- CVKD N/A
- Revenue Next Year
- NDLS $0.68
- CVKD N/A
- P/E Ratio
- NDLS N/A
- CVKD N/A
- Revenue Growth
- NDLS N/A
- CVKD N/A
- 52 Week Low
- NDLS $0.55
- CVKD $5.70
- 52 Week High
- NDLS $1.83
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- NDLS 52.86
- CVKD 47.47
- Support Level
- NDLS $0.66
- CVKD $11.00
- Resistance Level
- NDLS $0.82
- CVKD $13.24
- Average True Range (ATR)
- NDLS 0.07
- CVKD 1.13
- MACD
- NDLS 0.01
- CVKD 0.20
- Stochastic Oscillator
- NDLS 87.67
- CVKD 72.33
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.